98%
921
2 minutes
20
Background And Objectives: Refusals of care in dementia can be a source of distress for people with dementia and their caregivers. Informant-based measures to examine refusals of care are limited and often measure other behaviors such as agitation. We aimed to assess the validity and reliability of the newly developed, 14-item, Refusal of Care Informant Scale (RoCIS) and then use the scale to verify the most common refusal behaviors.
Research Design And Methods: Data from 129 dyads were analyzed. Dyad was defined as a person with advanced dementia either living in a care home or supported in their own home and their caregiver. Data about the person with dementia were gathered using informant-based questionnaires. The psychometric properties of the RoCIS were investigated using Rasch analysis to determine validity and reliability.
Results: Following Rasch analysis, the item "upset" was removed from the RoCIS. The reduced 13-item RoCIS is unidimensional and achieved a reliability index of 0.85 (Cronbach's alpha 0.88). Sixty-eight percent of people with dementia had refused care in the last month, with "verbally refused" the most common type of refusal behavior. People in the "very severe/profound" stage of dementia showed more refusal behaviors than those in the "severe" stage.
Discussion And Implications: Results provide initial evidence that the RoCIS is a valid and reliable informant-based scale measuring refusals of care in advanced dementia. Results indicate a need to develop new approaches and techniques to make assistance with personal care more acceptable to people with dementia.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474588 | PMC |
http://dx.doi.org/10.1093/geront/gnac066 | DOI Listing |
CNS Drugs
September 2025
Global Health Neurology Lab, Sydney, NSW, 2150, Australia.
Acute ischemic stroke (AIS) remains a leading cause of mortality and long-term disability globally, with survivors at high risk of recurrent stroke, cardiovascular events, and post-stroke dementia. Statins, while widely used for their lipid-lowering effects, also possess pleiotropic properties, including anti-inflammatory, endothelial-stabilizing, and neuroprotective actions, which may offer added benefit in AIS management. This article synthesizes emerging evidence on statins' dual mechanisms of action and evaluates their role in reducing recurrence, improving survival, and mitigating cognitive decline.
View Article and Find Full Text PDFSleep Adv
August 2025
Division of Public Health, Department of Family and Preventive Medicine, University of Utah, 303 Chipeta Way, Salt Lake City, UT 84013, United States of America.
Individuals with mild cognitive impairment (MCI) demonstrate cognitive decline without major functional impairment and are at increased risk for developing Alzheimer's disease and related dementias (ADRD). Sleep and biobehavioral rhythm disturbances (disruptions in 24-h oscillations in physiology and behavior, including rest-activity patterns and mealtimes) are more than twice as common among patients with MCI than cognitively intact older adults. Importantly, the consequences of sleep and biobehavioral rhythm disruption in MCI extend beyond the patient, also profoundly affecting the spouse/partner.
View Article and Find Full Text PDFBasic Clin Pharmacol Toxicol
October 2025
Department of Medical Pharmacology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.
Neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and frontotemporal dementia represent a significant global health burden with limited therapeutic options. Current treatments are primarily symptomatic and fail to modify disease progression, emphasizing the urgent need for novel, mechanism-based interventions. Recent advances in molecular neuroscience have identified several non-classical pathogenic pathways, including neuroinflammation, mitochondrial dysfunction, impaired autophagy and proteostasis, synaptic degeneration and non-coding RNA dysregulation.
View Article and Find Full Text PDFAlzheimers Dement
September 2025
Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Introduction: Antisocial behaviors occur in dementia, but the underlying neurocognitive mechanisms remain underexplored. We administered a decision-making task measuring patients' harm aversion by offering options to shock themselves or another person in exchange for money, hypothesizing that task performance would relate to antisocial behaviors and ventromedial/orbitofrontal cortex (vmPFC/OFC) atrophy.
Methods: Among 43 dementia patients (n = 23 behavioral variant frontotemporal dementia [bvFTD], n = 20 Alzheimer's disease [AD]), we used linear regressions to measure relationships between harm aversion and antisocial behavior, psychopathic personality traits, socioemotional functions, and vmPFC/OFC cortical thickness, controlling for age, sex, and cognitive dysfunction.
Alzheimers Dement
September 2025
Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
This review covers recent advances (2023-2024) in neuroimaging research into the pathophysiology, progression, and treatment of Alzheimer's disease (AD) and related dementias (ADRD). Despite the rapid emergence of blood-based biomarkers, neuroimaging continues to be a vital area of research in ADRD. Here, we discuss neuroimaging as a powerful tool to topographically visualize and quantify amyloid, tau, neurodegeneration, inflammation, and vascular disease in the brain.
View Article and Find Full Text PDF